(Sar¹)-Angiotensin II is a stabilized analog used to explore N-terminal structural constraints in angiotensin receptor interactions. Its sarcosine substitution influences backbone flexibility and binding geometry. Researchers use it to evaluate minimal motifs driving signal initiation. The peptide supports high-resolution analysis of angiotensin-family ligands.
CAT No: A15093
CAS No:51833-69-3
Synonyms/Alias:(Sar1)-Angiotensin II;51833-69-3;CHEMBL216061;Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH;MFCD00167493;(Sar 1)-Angiotensin II;HY-P3138;BDBM50011973;AKOS040754865;DA-59712;FS108527;MS-31855;CS-0148150;G12437;Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH; H-(Sar)RVYIHPF-OH;(Sar1)-Angiotensin II (H-Sar-DL-Arg-L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe-OH);(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid;
3. Cationic cell-penetrating peptides are potent furin inhibitors
5. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More